




**Figure S1.** Generation of *Stella*-knockout cell lines by CRISPR/Cas9-mediated genome editing. (A) Schematic diagram of sgRNA targeting sites. (B) PCR analysis of genomic DNA. (C) Sanger sequencing validation studies. (D) RT-PCR analysis of the *Stella* mRNA level.




**Figure S2.** Analysis of potential off-target sites. (A) T7E1 cleavage analysis of potential off-target sites for sgRNA1. M, DL2000; 1–5 represent potential off-target sites. (B) T7E1 cleavage analysis of potential off-target sites for sgRNA2. M, DL2000; 1–5 represent potential off-target sites. (C) Five potential off-target sites for sgRNA1 of stella were sequenced. Twenty base pairs of POTS and PAM are represented in shadow. (D) Five potential off-target sites for sgRNA2 of stella were sequenced. Twenty base pairs of POTS and PAM are represented in shadow.




**Figure S3.** Cell proliferation experiment of FGSCs in vitro. (A) EdU staining assays. (B) Quantification of EdU assay results. (C) CCK-8 assay. (D) Relative expression of *Etv5*, *Bcl6b*, *Oct4*, and *Akt* in FGSCs after *Stella* overexpression and knockout. KO-con, *Stella*-knockout control. KO, *Stella* knockout. over-con, *Stella*-overexpressing control. over, *Stella* overexpression.




**Figure S4.** Differential gene expression analysis by RNA-seq. **(A)** Principal component analysis (PCA) of gene expression profile of PGCs, GV oocytes, MII oocytes, *Stella*-knockout and -overexpression FGSCs. **(B)** RNA-seq data were identified by randomly selected genes. **(C, D)** Heatmap of the differentially expressed genes between *Stella*-knockout FGSCs **(C)** and *Stella*-overexpressing FGSCs **(D)** compared with the corresponding controls for each biological replicate. **(E, F)** KEGG pathway terms of differentially expressed genes in *Stella*-knockdown **(E)** and *Stella*-overexpressing FGSCs **(F)**. KO-con, *Stella*-knockout control. KO, *Stella* knockout. over-con, *Stella*-overexpressing control. over, *Stella* overexpression.




**Figure S5.** Scatter plots showing the correlation between DNA methylation and STELLA binding sites in FGSCs. The correlation between DNA methylation and ChIP-seq of STELLA was analyzed in KO-con FGSCs (**A**) and KO-con FGSCs (**B**), respectively. KO-con, *Stella*-knockout control. Over-con, *Stella*-overexpressing control.



**Figure S6.** *Stella* overexpression does not affect the formation of compartments. **(A)** Tracks of cis-eigenvector 1 values across the entirety of chromosome 19 are very similar between the *Stella*-overexpressing and control cells. **(B)** Pie chart showing the genomic compartment changes between *Stella*-overexpressing and control cells. Data sets “A” and “B” denote the open and closed compartments, respectively. “A to A” represents compartments that are open in both cell lines; “B to B” represents compartments that are closed in both cell lines; “A to B” denotes compartments that are open in control but closed in *Stella*-overexpressing cells; and “B to A” denotes compartments that are closed in control and open in *Stella*-overexpressing cells.



**Figure S7.** *Stella* overexpression does not affect the formation of TADs. **(A)** Number of TADs identified in control and *Stella*-overexpressing groups at 40 kb resolution. **(B)** Venn diagram showing that the numbers of TADs are largely similar between *Stella*-overexpressing and control groups. **(C)** Box plot showing the average size (kb) of TADs identified in control and *Stella*-overexpressing groups, both at 40 kb (t-test, p-value=0.6198). **(D)** Pie chart showing TAD switching between A/B compartments. “A to A” and “B to B” mean no switching of TADs; they remain in the same “A” and “B” compartments, respectively. “A to B” represents TADs switching from A-type in the control to B-type, and “B to A” represents TADs switching from B-type in the control to A-type in *Stella*-overexpressing groups. Unknown represents when the compartment status of TADs is not known.



**Figure S8.** *Stella* knockout reduces the TAD boundary strength in STELLA-associated regions. (A) Venn diagram showing that the numbers of TADs are largely similar between *Stella* knockout and control groups. (B) Genome-wide statistical analysis within TADs at 400 kb resolution. (C) A representative region showing contacts and TAD boundaries at 20 kb resolution. (D) Box plot showing that the TAD boundary intensity score was lower after *Stella* knockout. (E) Box plot showing the TAD boundary score distribution for the overlapping and specific TAD boundaries.